Single Dose Administration of L-Carnitine Improves Antioxidant Activities in Healthy Subjects
L-carnitine has been used as a supplement to treat cardiovascular or liver disease. However, there has been little information about the effect of L-carnitine on anti-oxidation capability in healthy human subjects. This study was designed to investigate the correlation between plasma L-carnitine con...
Saved in:
Published in | The Tohoku Journal of Experimental Medicine Vol. 224; no. 3; pp. 209 - 213 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
Japan
Tohoku University Medical Press
2011
|
Subjects | |
Online Access | Get full text |
ISSN | 0040-8727 1349-3329 1349-3329 |
DOI | 10.1620/tjem.224.209 |
Cover
Abstract | L-carnitine has been used as a supplement to treat cardiovascular or liver disease. However, there has been little information about the effect of L-carnitine on anti-oxidation capability in healthy human subjects. This study was designed to investigate the correlation between plasma L-carnitine concentration and antioxidant activity. Liquid L-carnitine (2.0 g) was administered orally as a single dose in 12 healthy subjects. Plasma concentration of L-carnitine was detected by HPLC. The baseline concentration of L-carnitine was 39.14 ± 5.65 μmol/L. After single oral administration, the maximum plasma concentration (Cmax) and area under the curve (AUC0-∞) were 84.7 ± 25.2 μmol/L and 2,676.4 ± 708.3 μmol/L·h, respectively. The half-life and the time required to reach the Cmax was 60.3 ± 15.0 min and 3.4 ± 0.46 h, respectively. There was a gradual increase in plasma concentrations of superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), catalase and total antioxidative capacity (T-AOC) in the first 3.5 h following L-carnitine administration. The plasma concentrations of SOD, GSH-Px, catalase and T-AOC returned to baseline levels within 24 h. A positive correlation was found between L-carnitine concentration and the antioxidant index of SOD (r = 0.992, P < 0.01), GSH-Px (r = 0.932, P < 0.01), catalase (r = 0.972, P < 0.01) or T-AOC (r = 0.934, P < 0.01). In conclusion, L-carnitine increases activities of antioxidant enzymes and the total antioxidant capacity in healthy subjects. It may be useful as a supplementary therapy for chronic illnesses involving excessive oxidative stress. |
---|---|
AbstractList | L-carnitine has been used as a supplement to treat cardiovascular or liver disease. However, there has been little information about the effect of L-carnitine on anti-oxidation capability in healthy human subjects. This study was designed to investigate the correlation between plasma L-carnitine concentration and antioxidant activity. Liquid L-carnitine (2.0 g) was administered orally as a single dose in 12 healthy subjects. Plasma concentration of L-carnitine was detected by HPLC. The baseline concentration of L-carnitine was 39.14 ± 5.65 μmol/L. After single oral administration, the maximum plasma concentration (Cmax) and area under the curve (AUC0-∞) were 84.7 ± 25.2 μmol/L and 2,676.4 ± 708.3 μmol/L·h, respectively. The half-life and the time required to reach the Cmax was 60.3 ± 15.0 min and 3.4 ± 0.46 h, respectively. There was a gradual increase in plasma concentrations of superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), catalase and total antioxidative capacity (T-AOC) in the first 3.5 h following L-carnitine administration. The plasma concentrations of SOD, GSH-Px, catalase and T-AOC returned to baseline levels within 24 h. A positive correlation was found between L-carnitine concentration and the antioxidant index of SOD (r = 0.992, P < 0.01), GSH-Px (r = 0.932, P < 0.01), catalase (r = 0.972, P < 0.01) or T-AOC (r = 0.934, P < 0.01). In conclusion, L-carnitine increases activities of antioxidant enzymes and the total antioxidant capacity in healthy subjects. It may be useful as a supplementary therapy for chronic illnesses involving excessive oxidative stress. L-carnitine has been used as a supplement to treat cardiovascular or liver disease. However, there has been little information about the effect of L-carnitine on anti-oxidation capability in healthy human subjects. This study was designed to investigate the correlation between plasma L-carnitine concentration and antioxidant activity. Liquid L-carnitine (2.0 g) was administered orally as a single dose in 12 healthy subjects. Plasma concentration of L-carnitine was detected by HPLC. The baseline concentration of L-carnitine was 39.14 ± 5.65 µmol/L. After single oral administration, the maximum plasma concentration (C(max)) and area under the curve (AUC(0-∞)) were 84.7 ± 25.2 µmol/L and 2,676.4 ± 708.3 µmol/L·h, respectively. The half-life and the time required to reach the C(max) was 60.3 ± 15.0 min and 3.4 ± 0.46 h, respectively. There was a gradual increase in plasma concentrations of superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), catalase and total antioxidative capacity (T-AOC) in the first 3.5 h following L-carnitine administration. The plasma concentrations of SOD, GSH-Px, catalase and T-AOC returned to baseline levels within 24 h. A positive correlation was found between L-carnitine concentration and the antioxidant index of SOD (r = 0.992, P < 0.01), GSH-Px (r = 0.932, P < 0.01), catalase (r = 0.972, P < 0.01) or T-AOC (r = 0.934, P < 0.01). In conclusion, L-carnitine increases activities of antioxidant enzymes and the total antioxidant capacity in healthy subjects. It may be useful as a supplementary therapy for chronic illnesses involving excessive oxidative stress. L-carnitine has been used as a supplement to treat cardiovascular or liver disease. However, there has been little information about the effect of L-carnitine on anti-oxidation capability in healthy human subjects. This study was designed to investigate the correlation between plasma L-carnitine concentration and antioxidant activity. Liquid L-carnitine (2.0 g) was administered orally as a single dose in 12 healthy subjects. Plasma concentration of L-carnitine was detected by HPLC. The baseline concentration of L-carnitine was 39.14 ± 5.65 µmol/L. After single oral administration, the maximum plasma concentration (C(max)) and area under the curve (AUC(0-∞)) were 84.7 ± 25.2 µmol/L and 2,676.4 ± 708.3 µmol/L·h, respectively. The half-life and the time required to reach the C(max) was 60.3 ± 15.0 min and 3.4 ± 0.46 h, respectively. There was a gradual increase in plasma concentrations of superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), catalase and total antioxidative capacity (T-AOC) in the first 3.5 h following L-carnitine administration. The plasma concentrations of SOD, GSH-Px, catalase and T-AOC returned to baseline levels within 24 h. A positive correlation was found between L-carnitine concentration and the antioxidant index of SOD (r = 0.992, P < 0.01), GSH-Px (r = 0.932, P < 0.01), catalase (r = 0.972, P < 0.01) or T-AOC (r = 0.934, P < 0.01). In conclusion, L-carnitine increases activities of antioxidant enzymes and the total antioxidant capacity in healthy subjects. It may be useful as a supplementary therapy for chronic illnesses involving excessive oxidative stress.L-carnitine has been used as a supplement to treat cardiovascular or liver disease. However, there has been little information about the effect of L-carnitine on anti-oxidation capability in healthy human subjects. This study was designed to investigate the correlation between plasma L-carnitine concentration and antioxidant activity. Liquid L-carnitine (2.0 g) was administered orally as a single dose in 12 healthy subjects. Plasma concentration of L-carnitine was detected by HPLC. The baseline concentration of L-carnitine was 39.14 ± 5.65 µmol/L. After single oral administration, the maximum plasma concentration (C(max)) and area under the curve (AUC(0-∞)) were 84.7 ± 25.2 µmol/L and 2,676.4 ± 708.3 µmol/L·h, respectively. The half-life and the time required to reach the C(max) was 60.3 ± 15.0 min and 3.4 ± 0.46 h, respectively. There was a gradual increase in plasma concentrations of superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), catalase and total antioxidative capacity (T-AOC) in the first 3.5 h following L-carnitine administration. The plasma concentrations of SOD, GSH-Px, catalase and T-AOC returned to baseline levels within 24 h. A positive correlation was found between L-carnitine concentration and the antioxidant index of SOD (r = 0.992, P < 0.01), GSH-Px (r = 0.932, P < 0.01), catalase (r = 0.972, P < 0.01) or T-AOC (r = 0.934, P < 0.01). In conclusion, L-carnitine increases activities of antioxidant enzymes and the total antioxidant capacity in healthy subjects. It may be useful as a supplementary therapy for chronic illnesses involving excessive oxidative stress. |
Author | Wang, Chun-bo Cao, Yu Qu, Hai-jun Li, Ping Han, Zhi-wu Wang, Le-xin |
Author_xml | – sequence: 1 fullname: Qu, Hai-jun organization: Department of Pharmacy, the Affiliated Hospital of Medical College, Qingdao University – sequence: 1 fullname: Han, Zhi-wu organization: Department of Pharmacy, the Affiliated Hospital of Medical College, Qingdao University – sequence: 1 fullname: Li, Ping organization: Department of Pharmacy, the Affiliated Hospital of Medical College, Qingdao University – sequence: 1 fullname: Wang, Le-xin organization: School of Biomedical Sciences, Charles Sturt University – sequence: 1 fullname: Wang, Chun-bo organization: Department of Pharmacology, Medical College, Qingdao University – sequence: 1 fullname: Cao, Yu organization: Department of Pharmacy, the Affiliated Hospital of Medical College, Qingdao University |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/21701126$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kE1PGzEQhq0KVALtrWfkWy_d4I_d9e4xTaFEisQBOFaW7R0njna9YDuo_PuaJgEJicuMNO8zo9Fzio786AGhb5RMac3IRdrAMGWsnDLSfkITysu24Jy1R2hCSEmKRjBxgk5j3BDCSyLqz-iEUUEoZfUE_bl1ftUD_jVGwLNucN7FFFRyo8ejxctiroJ3yXnAi-EhjE8Q8czn-K_rlE94ZpJ7ynkeO4-vQfVp_Yxvt3oDJsUv6NiqPsLXfT9D91eXd_PrYnnzezGfLQtTiSYVlYWOQdXxzlZU284oauuaV6JmWtu21Ex3TdOWhIrWWKoZ1LbSQpdtSSujBD9D33d384ePW4hJDi4a6HvlYdxG2QguSE0IzeT5ntzqATr5ENygwrM8GMkA2wEmjDEGsNK49N9H1uJ6SYl80S5ftMusXWbteenHu6XD3Q_wnzt8E5NawSusQnKmhzeYHyppX0OzVkGC5_8AATqdPg |
CitedBy_id | crossref_primary_10_1080_10408398_2023_2178379 crossref_primary_10_1111_1750_3841_12553 crossref_primary_10_2174_1574888X17666220511141123 crossref_primary_10_1089_aivt_2023_0012 crossref_primary_10_3389_fvets_2022_860771 crossref_primary_10_1590_S1984_82502013000100020 crossref_primary_10_1016_j_pestbp_2025_106301 crossref_primary_10_3390_ijms21239168 crossref_primary_10_3390_nu10030349 crossref_primary_10_3390_nu13103432 crossref_primary_10_3390_jpm13020298 crossref_primary_10_1002_ptr_6568 crossref_primary_10_1080_21655979_2020_1863618 crossref_primary_10_1038_ejcn_2017_131 crossref_primary_10_1111_bcpt_12112 crossref_primary_10_1007_s11011_025_01545_6 crossref_primary_10_1007_s11259_016_9670_9 crossref_primary_10_1016_j_foodres_2016_08_007 crossref_primary_10_1139_apnm_2014_0163 crossref_primary_10_1208_s12249_020_01852_4 crossref_primary_10_1016_j_eujim_2020_101243 crossref_primary_10_1097_MBC_0000000000000760 crossref_primary_10_1016_j_nutres_2015_06_003 crossref_primary_10_1007_s13205_023_03714_9 crossref_primary_10_1089_bio_2023_0031 crossref_primary_10_1186_1475_2891_13_79 crossref_primary_10_1021_acsinfecdis_1c00162 crossref_primary_10_1016_j_heliyon_2024_e25057 crossref_primary_10_1016_j_tice_2024_102558 crossref_primary_10_1016_j_scispo_2016_02_005 crossref_primary_10_3390_nu15112587 crossref_primary_10_1007_s13277_013_1477_5 crossref_primary_10_1186_s41100_017_0135_6 crossref_primary_10_1519_JSC_0b013e318234ebcb crossref_primary_10_1016_j_ctim_2018_03_003 crossref_primary_10_1080_21678421_2020_1726565 crossref_primary_10_3390_antiox9121310 crossref_primary_10_1042_BSR20191601 crossref_primary_10_1002_jpn3_12351 |
Cites_doi | 10.1016/S0378-4347(96)00219-8 10.1177/0091270006292851 10.1016/j.transproceed.2007.03.112 10.1016/j.jss.2005.12.017 10.7326/0003-4819-107-4-526 10.1042/0264-6021:3610417 10.1016/0026-0495(91)90033-S 10.1016/S0378-4347(97)00376-9 10.1002/jps.2600840520 10.1016/j.lfs.2005.05.103 10.1136/bjsm.2007.039792 10.2165/00002512-199303010-00006 10.1152/ajpcell.00333.2003 10.1016/j.cca.2006.11.008 10.3109/10408369209114601 10.1007/BF02993974 10.1093/ndt/gfi257 |
ContentType | Journal Article |
Copyright | 2011 Tohoku University Medical Press |
Copyright_xml | – notice: 2011 Tohoku University Medical Press |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1620/tjem.224.209 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1349-3329 |
EndPage | 213 |
ExternalDocumentID | 21701126 10_1620_tjem_224_209 article_tjem_224_3_224_3_209_article_char_en |
Genre | Clinical Trial Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- -~X .55 .GJ 123 29Q 2WC 36B 3O- 53G 5RE 7.U ABCQX ACGFO ADBBV AEGXH AENEX AIAGR ALMA_UNASSIGNED_HOLDINGS BAWUL CS3 DIK DU5 E3Z EBD EMB EMOBN F5P GX1 JSF JSH KQ8 L7B MK0 OK1 OVT P2P RJT RNS RZJ SV3 TKC TR2 W2D WH7 X7J X7M XSB ZGI ZXP AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
ID | FETCH-LOGICAL-c578t-5fed2e5d3df51bfdca1f6635762bbf94b2bd88940179cf1b2e6f5b7b49415ca73 |
ISSN | 0040-8727 1349-3329 |
IngestDate | Fri Jul 11 04:17:53 EDT 2025 Mon Jul 21 05:59:36 EDT 2025 Tue Jul 01 01:28:51 EDT 2025 Thu Apr 24 22:58:58 EDT 2025 Wed Sep 03 06:12:44 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c578t-5fed2e5d3df51bfdca1f6635762bbf94b2bd88940179cf1b2e6f5b7b49415ca73 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
OpenAccessLink | https://www.jstage.jst.go.jp/article/tjem/224/3/224_3_209/_article/-char/en |
PMID | 21701126 |
PQID | 873706001 |
PQPubID | 23479 |
PageCount | 5 |
ParticipantIDs | proquest_miscellaneous_873706001 pubmed_primary_21701126 crossref_citationtrail_10_1620_tjem_224_209 crossref_primary_10_1620_tjem_224_209 jstage_primary_article_tjem_224_3_224_3_209_article_char_en |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2011-00-00 |
PublicationDateYYYYMMDD | 2011-01-01 |
PublicationDate_xml | – year: 2011 text: 2011-00-00 |
PublicationDecade | 2010 |
PublicationPlace | Japan |
PublicationPlace_xml | – name: Japan |
PublicationTitle | The Tohoku Journal of Experimental Medicine |
PublicationTitleAlternate | Tohoku J. Exp. Med. |
PublicationYear | 2011 |
Publisher | Tohoku University Medical Press |
Publisher_xml | – name: Tohoku University Medical Press |
References | Cross, C.E., Halliwell, B., Borish, E.T., Pryor, W.A., Ames, B.N., Saul, R.L., McCord, J.M. & Harman, D. (1987) Oxygen radicals and human disease. Ann. Intern. Med., 107, 526-545. Longo, A., Bruno, G., Curti, S., Mancinelli, A. & Miotto, G. (1996) Determination of L-carnitine, acetyl-L-carnitine and propionyl-L-carnitine in human plasma by high-performance liquid chromatography after pre-column derivatization with 1-aminoanthracen. J. Chromatogr. B Biomed. Appl., 686, 129-139. Van Kempen, T.A. & Odle, J. (1992) Quantification of carnitine esters by high-performance liquid chromatography: effect of feeding medium-chain triglycerides on the plasma carnitine ester profile. J. Chromatogr., 584, 157-165. Vaz, F.M. & Wanders, R.J. (2002) Carnitine biosynthesis in mammals. Biochem. J., 361, 417-429. Cao, Q.R., Ren, S., Park, M.J., Choi, Y.J. & Lee, B.J. (2007) Determination of highly soluble L-Carnitine in biological samples by reverse phase high performance liquid chromatography with fluorescent derivatization. Arch. Pharm. Res., 30, 1041-1046. Sahajwalla, C.G., Helton, E.D., Purich, E.D., Hoppel, C.L. & Cabana, B.E. (1995) Multiple-dose pharmacokinetics and bioequivalence of L-carnitine 330 mg tablet versus 1 g chewable tablet versus enteral solution in healthy adult male volunteers. J. Pharm. Sci., 84, 627-633. Biolo, G., Stulle, M., Bianco, F., Mengozzi, G., Barazzoni, R., Vasile, A., Panzetta, G. & Guarnieri, G. (2008) Insulin action on glucose and protein metabolism during L-carnitine supplementation in maintenance haemodialysis patients. Nephrol. Dial. Transplant., 23, 991-997. Lahjouji, K., Elimrani, I., Lafond, J., Leduc, L., Qureshi, I.A. & Mitchell, G.A. (2004) L-Carnitine transport in human placental brush-border membranes is mediated by the sodium-dependent organic cation transporter OCTN2. Am. J. Physiol. Cell Physiol., 287, C263-C269. Marzo, A. & Curti, S. (1997) L-carnitine moiety assay: an up-to-date reappraisal covering the commonest methods for various applications. J. Chromatogr. B Biomed. Sci. Appl., 702, 1-20. Minker, P.E. & Hoppel, C.L. (1993) Quantification of carnitine and specific acylcarnitines by high-performance liquid chromatography: application to normal human urine and urine from patients with methylmalonic aciduria, isovaleric acidemia or medium-chain acyl-CoA dehydrogenase deficiency. J. Chromatogr., 613, 203-221. Tsakiris, T., Angelogianni, P., Tesseromatis, C., Tsakiris, S. & Schulpis, K.H. (2008) Effect of L-carnitine administration on the modulated rat brain protein concentration, acetylcholinesterase, Na+K+-ATPase and Mg2+-ATPase activities induced by forced swimming. Br. J. Sports Med., 42, 367-372. Rebouche, C.J. (1991) Quantitative estimation of absorption and degradation of a carnitine supplement by human adults. Metabolism, 40, 1305-1310. Vernez, L., Dickenmann, M., Steiger, J., Wenk, M. & Krähenbühl, S. (2006) Effect of L-carnitine on the kinetics of carnitine, acylcarnitines and butyrobetaine in long-term haemodialysis. Nephrol. Dial. Transplant., 21, 450-458. Harman, D. (1993) Free radical involvement in aging. Pathophysiology and therapeutic implications. Drugs Aging, 3, 60-80. Irshad, M. & Chaudhuri, P.S. (2002) Oxidant-antioxidant system: role and significance in human body. Indian J. Exp. Biol., 40, 1233-1239. Akin, M., Kurukahvecioglu, O., Gulbahar, O., Isikgonul, I., Taneri, F., Tezel, E. & Onuk, E. (2007) Comparison of the effects of sodium nitroprusside and L-carnitine in experimental ischemia-reperfusion injury in rats. Transplant. Proc., 9, 2997-3001. Li, K., Li, W. & Huang, Y. (2007) Determination of free L-carnitine in human seminal plasma by high performance liquid chromatography with pre-column ultraviolet derivatization and its clinical application in male infertility. Clin. Chim. Acta, 378, 159-163. Onem, G., Aral, E., Enli, Y., Oguz, E.O., Coskun, E., Aybek, H., Ozcan, A.V., Sacar, M., Bir, L.S., Baltalarli, A. & Baycu, C. (2006) Neuroprotective effects of L-carnitine and vitamin E alone or in combination against ischemia-reperfusion injury in rats. J. Surg. Res., 131, 124-130. Angelini, C., Vergani, L. & Martinuzzi, A. (1992) Clinical and biochemical aspects of carnitine deficiency and insufficiency: transport defects and inborn errors of β-oxidation. Crit. Rev. Clin. Lab. Sci., 29, 217-242. Gulcin, I. (2006) Antioxidant and antiradical activities of l-carnitine. Life Sci., 78, 803-811. Takeyama, N., Matsuo, N., Takagi, D. & Tanaka, T. (1989) Determination of overt carnitine palmitoyltransferase by reversed-phase high-performance liquid chromatography. J. Chromatogr., 491, 69-76. Bain, M.A., Milne, R.W. & Evans, A.M. (2006) Disposition and metabolite kinetics of oral L-carnitine in humans. J. Clin. Pharmacol., 46, 1163-1170. 11 22 12 13 15 16 17 19 (18) 1989; 491 1 2 3 (20) 1992; 584 4 5 6 7 8 9 (14) 1993; 613 10 21 |
References_xml | – reference: Minker, P.E. & Hoppel, C.L. (1993) Quantification of carnitine and specific acylcarnitines by high-performance liquid chromatography: application to normal human urine and urine from patients with methylmalonic aciduria, isovaleric acidemia or medium-chain acyl-CoA dehydrogenase deficiency. J. Chromatogr., 613, 203-221. – reference: Onem, G., Aral, E., Enli, Y., Oguz, E.O., Coskun, E., Aybek, H., Ozcan, A.V., Sacar, M., Bir, L.S., Baltalarli, A. & Baycu, C. (2006) Neuroprotective effects of L-carnitine and vitamin E alone or in combination against ischemia-reperfusion injury in rats. J. Surg. Res., 131, 124-130. – reference: Akin, M., Kurukahvecioglu, O., Gulbahar, O., Isikgonul, I., Taneri, F., Tezel, E. & Onuk, E. (2007) Comparison of the effects of sodium nitroprusside and L-carnitine in experimental ischemia-reperfusion injury in rats. Transplant. Proc., 9, 2997-3001. – reference: Angelini, C., Vergani, L. & Martinuzzi, A. (1992) Clinical and biochemical aspects of carnitine deficiency and insufficiency: transport defects and inborn errors of β-oxidation. Crit. Rev. Clin. Lab. Sci., 29, 217-242. – reference: Sahajwalla, C.G., Helton, E.D., Purich, E.D., Hoppel, C.L. & Cabana, B.E. (1995) Multiple-dose pharmacokinetics and bioequivalence of L-carnitine 330 mg tablet versus 1 g chewable tablet versus enteral solution in healthy adult male volunteers. J. Pharm. Sci., 84, 627-633. – reference: Lahjouji, K., Elimrani, I., Lafond, J., Leduc, L., Qureshi, I.A. & Mitchell, G.A. (2004) L-Carnitine transport in human placental brush-border membranes is mediated by the sodium-dependent organic cation transporter OCTN2. Am. J. Physiol. Cell Physiol., 287, C263-C269. – reference: Longo, A., Bruno, G., Curti, S., Mancinelli, A. & Miotto, G. (1996) Determination of L-carnitine, acetyl-L-carnitine and propionyl-L-carnitine in human plasma by high-performance liquid chromatography after pre-column derivatization with 1-aminoanthracen. J. Chromatogr. B Biomed. Appl., 686, 129-139. – reference: Bain, M.A., Milne, R.W. & Evans, A.M. (2006) Disposition and metabolite kinetics of oral L-carnitine in humans. J. Clin. Pharmacol., 46, 1163-1170. – reference: Li, K., Li, W. & Huang, Y. (2007) Determination of free L-carnitine in human seminal plasma by high performance liquid chromatography with pre-column ultraviolet derivatization and its clinical application in male infertility. Clin. Chim. Acta, 378, 159-163. – reference: Harman, D. (1993) Free radical involvement in aging. Pathophysiology and therapeutic implications. Drugs Aging, 3, 60-80. – reference: Rebouche, C.J. (1991) Quantitative estimation of absorption and degradation of a carnitine supplement by human adults. Metabolism, 40, 1305-1310. – reference: Cao, Q.R., Ren, S., Park, M.J., Choi, Y.J. & Lee, B.J. (2007) Determination of highly soluble L-Carnitine in biological samples by reverse phase high performance liquid chromatography with fluorescent derivatization. Arch. Pharm. Res., 30, 1041-1046. – reference: Tsakiris, T., Angelogianni, P., Tesseromatis, C., Tsakiris, S. & Schulpis, K.H. (2008) Effect of L-carnitine administration on the modulated rat brain protein concentration, acetylcholinesterase, Na+K+-ATPase and Mg2+-ATPase activities induced by forced swimming. Br. J. Sports Med., 42, 367-372. – reference: Cross, C.E., Halliwell, B., Borish, E.T., Pryor, W.A., Ames, B.N., Saul, R.L., McCord, J.M. & Harman, D. (1987) Oxygen radicals and human disease. Ann. Intern. Med., 107, 526-545. – reference: Takeyama, N., Matsuo, N., Takagi, D. & Tanaka, T. (1989) Determination of overt carnitine palmitoyltransferase by reversed-phase high-performance liquid chromatography. J. Chromatogr., 491, 69-76. – reference: Van Kempen, T.A. & Odle, J. (1992) Quantification of carnitine esters by high-performance liquid chromatography: effect of feeding medium-chain triglycerides on the plasma carnitine ester profile. J. Chromatogr., 584, 157-165. – reference: Gulcin, I. (2006) Antioxidant and antiradical activities of l-carnitine. Life Sci., 78, 803-811. – reference: Vaz, F.M. & Wanders, R.J. (2002) Carnitine biosynthesis in mammals. Biochem. J., 361, 417-429. – reference: Biolo, G., Stulle, M., Bianco, F., Mengozzi, G., Barazzoni, R., Vasile, A., Panzetta, G. & Guarnieri, G. (2008) Insulin action on glucose and protein metabolism during L-carnitine supplementation in maintenance haemodialysis patients. Nephrol. Dial. Transplant., 23, 991-997. – reference: Vernez, L., Dickenmann, M., Steiger, J., Wenk, M. & Krähenbühl, S. (2006) Effect of L-carnitine on the kinetics of carnitine, acylcarnitines and butyrobetaine in long-term haemodialysis. Nephrol. Dial. Transplant., 21, 450-458. – reference: Irshad, M. & Chaudhuri, P.S. (2002) Oxidant-antioxidant system: role and significance in human body. Indian J. Exp. Biol., 40, 1233-1239. – reference: Marzo, A. & Curti, S. (1997) L-carnitine moiety assay: an up-to-date reappraisal covering the commonest methods for various applications. J. Chromatogr. B Biomed. Sci. Appl., 702, 1-20. – ident: 4 – ident: 12 doi: 10.1016/S0378-4347(96)00219-8 – ident: 3 doi: 10.1177/0091270006292851 – volume: 613 start-page: 203 issn: 0021-9673 issue: 2 year: 1993 ident: 14 – volume: 584 start-page: 157 issn: 0021-9673 issue: 2 year: 1992 ident: 20 – ident: 1 doi: 10.1016/j.transproceed.2007.03.112 – ident: 15 doi: 10.1016/j.jss.2005.12.017 – ident: 6 doi: 10.7326/0003-4819-107-4-526 – ident: 21 doi: 10.1042/0264-6021:3610417 – ident: 16 doi: 10.1016/0026-0495(91)90033-S – ident: 13 doi: 10.1016/S0378-4347(97)00376-9 – ident: 17 doi: 10.1002/jps.2600840520 – ident: 7 doi: 10.1016/j.lfs.2005.05.103 – ident: 19 doi: 10.1136/bjsm.2007.039792 – ident: 8 doi: 10.2165/00002512-199303010-00006 – ident: 10 doi: 10.1152/ajpcell.00333.2003 – ident: 11 doi: 10.1016/j.cca.2006.11.008 – volume: 491 start-page: 69 issn: 0021-9673 issue: 1 year: 1989 ident: 18 – ident: 9 – ident: 2 doi: 10.3109/10408369209114601 – ident: 5 doi: 10.1007/BF02993974 – ident: 22 doi: 10.1093/ndt/gfi257 |
SSID | ssj0034076 |
Score | 2.1324708 |
Snippet | L-carnitine has been used as a supplement to treat cardiovascular or liver disease. However, there has been little information about the effect of L-carnitine... |
SourceID | proquest pubmed crossref jstage |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 209 |
SubjectTerms | Administration, Oral Antioxidants - metabolism Carnitine - administration & dosage Carnitine - blood Carnitine - pharmacokinetics Carnitine - pharmacology catalase Catalase - metabolism Dose-Response Relationship, Drug glutathione peroxidase Glutathione Peroxidase - metabolism Health Humans L-carnitine superoxide dismutase Superoxide Dismutase - metabolism Time Factors total antioxidative capacity |
Title | Single Dose Administration of L-Carnitine Improves Antioxidant Activities in Healthy Subjects |
URI | https://www.jstage.jst.go.jp/article/tjem/224/3/224_3_209/_article/-char/en https://www.ncbi.nlm.nih.gov/pubmed/21701126 https://www.proquest.com/docview/873706001 |
Volume | 224 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
ispartofPNX | The Tohoku Journal of Experimental Medicine, 2011, Vol.224(3), pp.209-213 |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bi9NAFB7KKuKLeLfemAd9WqYmM5MbPi1FXYQVwS7UBwmZzGS3dU3EJiC--Nc9Z2aSpusurEIJJZ1J2pyv3zlz5lwIeaFDnchYJswE2jAppGaFzkqWaMNVFpZFZkspHX2ID4_l-2W0nEx-j6KWulbNyl8X5pX8j1ThHMgVs2T_QbLDReEEvAf5whEkDMcryfgT6J0zA0YwVhfZqYJrXf9sjm6PFu1I5zswGywWsGp-rjQ80P2D0raOWNmYLJ-QZKkEfTObsdm6aE6br924zMROZ4DzG_TzwjpgP3dbt6pVccWKrbttDJANJPjY607r1XfMMz_taqaasUfCc6XnVxkAv7ps_5lxlCpkxoTwfg3PudwlTntwiTGDBtlIGXOXqPoXz8ccAyPbtfk2g0vNhknjctrn1NwQfIjLHpif4-wcZuccE0Cv8SSOsQXGu-UQIyRgtRv3YZf4s3zmBMx-Nb73jk1zfQ1m_Ym5fMViLZfFbXLLLznogcPPHTIx9V1y48jL7B754mBEEUZ0F0a0qegIRrSHER3BiG5hRFc19TCiPYzuk-O3bxbzQ-a7brAS2LtlUWU0N5EWuopCVemyCCs0S0FrKlVlUnGl0zSTSOVlFSpu4ipSiZIZ2IJlkYgHZK9uavOIUJEmVZAFUVBEUhquC5WIUFemSKWWSpdTst8_t7z0JemxM8pZfpGMpuTlMPq7K8VyybjXTgTDKP8H3Y4S_THIhg8xyxFIZUpoL7ccmBa3z4raNN0mTxOBpaaCcEoeOnkON-DY1SDk8eMrfsUn5Kbbm8DXU7LX_ujMMzBuW_XcAvAPc0KpvQ |
linkProvider | Geneva Foundation for Medical Education and Research |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Single+Dose+Administration+of+L-Carnitine+Improves+Antioxidant+Activities+in+Healthy+Subjects&rft.jtitle=Tohoku+journal+of+experimental+medicine&rft.au=Cao%2C+Yu&rft.au=Qu%2C+Hai-jun&rft.au=Li%2C+Ping&rft.au=Wang%2C+Chun-bo&rft.date=2011&rft.issn=0040-8727&rft.eissn=1349-3329&rft.volume=224&rft.issue=3&rft.spage=209&rft.epage=213&rft_id=info:doi/10.1620%2Ftjem.224.209&rft.externalDBID=n%2Fa&rft.externalDocID=10_1620_tjem_224_209 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0040-8727&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0040-8727&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0040-8727&client=summon |